PharmaWave is a business development company with operations in London and Tokyo. We focus on partnering in the regenerative medicine sector, working closely with clients to maximize the commercial potential of innovative therapies.

Japan aims to become a global leader in the field of regenerative medicine.

The government has recently enacted legislation changing the dynamics of the clinical application of regenerative medicine therapies. Conditional approval may be granted to therapeutic candidates if small Phase I/II clinical studies can demonstrate safety and probable benefit. Approval timeframes could be shortened to around 3 to 4 years.

This favourable regulatory environment creates exciting opportunities for foreign companies seeking access to the Japanese market through partnering.

PharmaWave helps companies find the right development and commercialisation partners. We serve as the point of contact in Japan, where local presence is essential to follow-up initiatives. We support the entire process, from introductions to deal completion.

We are committed to our clients’ partnering objectives, adopting flexible business models and risk sharing schemes.